Clinical Trial: Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases
Study Status: Completed
Recruit Status: Completed
Study Type: Interventional
Official Title: Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases
Brief Summary: Exploratory study to examine the effect(s) of Imatinib mesylate treatment on life threatening rare diseases with known associations to one or more Imatinib mesylate -sensitive tyrosine kinases, and to identify the contribution of specific protein tyrosine kinases (PTKs) of that specific disease.
Detailed Summary:
Sponsor: Novartis Pharmaceuticals
Current Primary Outcome:
- To examine the effect(s) of Imatinib mesylate treatment on life threatening rare diseases with known associations to one or more Imatinib mesylate-sensitive tyrosine kinases
- To identify the contribution of specific protein tyrosine kinases (PTKs) of that specific disease
Original Primary Outcome:
Current Secondary Outcome:
- To assess the safety and tolerability of Imatinib mesylate
- To evaluate the pharmacokinetic profile of Imatinib mesylate
- To assess, where feasible, the functional significance of relevant signal-transduction components in target tissues
Original Secondary Outcome:
Information By: Novartis
Dates:
Date Received: September 9, 2005
Date Started: February 2001
Date Completion:
Last Updated: November 16, 2016
Last Verified: November 2016
